Recherche et contributions académiques

📖 ARTICLE PUBLIÉ · JOURNAL OF SEXUAL MEDICINE · 2026

Clinical drivers and outcomes of first-presentation erectile dysfunction in octogenarians: a 15-year retrospective cohort study at a tertiary center

Auteurs : Weerasopone S, Coady PJ, Walia A, Hernandez BS, Khera M

Référence : The Journal of Sexual Medicine, volume 23, numéro 9, septembre 2026, qdag273 · Publié le 7 septembre 2026

Affiliations : Scott Department of Urology, Baylor College of Medicine, Houston, Texas, États-Unis · Bangkok Hospital Headquarters, Bangkok, Thaïlande

Rôle : Premier auteur

Portée : Une cohorte rétrospective sur quinze ans portant sur des hommes ayant consulté pour la première fois pour une dysfonction érectile alors qu'ils étaient octogénaires, examinant les facteurs cliniques à l'origine de cette première consultation et les modalités d'escalade thérapeutique. Le travail associé a été retenu comme finaliste du prix Sushil Lacy Manuscript au congrès 2026 de la South Central Section de l'AUA.

DOI : 10.1093/jsxmed/qdag273 · Accès sur abonnement auprès de l'éditeur.

📖 PUBLISHED ARTICLE · SEXUAL MEDICINE · OPEN ACCESS · 2026

L'impact de l'obésité et de l'apnée obstructive du sommeil sur l'hémodynamique vasculaire chez les hommes de moins de 40 ans : une étude de cohorte rétrospective sur 15 ans

Auteurs : Weerasopone S, Coady PJ, Walia A, Hernandez BS, Khera M

Citation: Sexual Medicine, Volume 14, Issue 6, December 2026, qfag086 · Published 14 September 2026

Affiliations : Scott Department of Urology, Baylor College of Medicine, Houston, Texas, États-Unis · Bangkok Hospital Headquarters, Bangkok, Thaïlande

Rôle : Premier auteur

Scope: A 15-year retrospective cohort of men under 40 undergoing penile duplex ultrasound, examining obesity and obstructive sleep apnea against measured penile vascular function.

DOI: 10.1093/sexmed/qfag086 · Open access.

📖 ARTICLE PUBLIÉ · 2023

Validation de la version thaïlandaise du Questionnaire sur l'Impact de l'Incontinence (IIQ-7) et de l'Inventaire des Troubles Urogénitaux (UDI-6)

Authors: Weerasopone S, Santingamkul A

Journal: Chulalongkorn Medical Journal (Chula Med J), Vol. 60, No. 4 · Published August 25, 2023

Affiliation: Division of Urology, Department of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand

Rôle : Premier auteur

Summary: This validation study confirmed that the Thai IIQ-7 and UDI-6 are reliable, valid, and consistent instruments for assessing symptom severity and the impact on quality of life in Thai patients with urinary incontinence — making these clinically essential tools available for the Thai-speaking population.

📖 ARTICLE PUBLIÉ · JOURNAL OF SEXUAL MEDICINE · 2026

Traitement substitutif par testostérone chez les octogénaires de sexe masculin : résultats cliniques et taux d'événements indésirables

Auteurs : Coady PJ, Walia A, Oppenheimer A, Hernandez BS, Chidananda R, Hinojosa-Gonzalez DE, Weerasopone S, Kohn T, Khera M

Citation: The Journal of Sexual Medicine, Volume 23, Issue 9, September 2026, qdag258 · Published 22 August 2026

Affiliation: Scott Department of Urology, Baylor College of Medicine, Houston, Texas, USA

Role: Co-Author

What the study asked: Men aged 80 and over are almost entirely absent from the trials that guide testosterone prescribing — both TRAVERSE and the T-Trials excluded or did not report separately on them, and both excluded men with a history of prostate cancer. This single-centre retrospective cohort followed 46 hypogonadal men aged 80 or older through 36 months of treatment.

What it found: Monitoring findings were reassuring. No patient reached a haematocrit of 54% or above, the threshold that usually forces treatment to change, and there was no biopsy-confirmed prostate cancer recurrence — notable because 39% of the cohort had a prostate cancer history. Blood pressure changed modestly overall (median +3 mmHg systolic), though six men rose by at least 20 mmHg, which is why blood pressure and haematocrit monitoring remain necessary rather than optional in this age group. All-cause mortality was 8.7% and 28.3% stopped treatment over the three years.

What it cannot show: The authors are explicit about the limits. There was no untreated comparison group, so the cardiovascular and thromboembolic events cannot be attributed to the treatment rather than to a medically complex population — 60.9% had hypertension and 30.4% coronary artery disease at baseline. The sample is small, the setting is a single centre, and the retrospective design means events treated elsewhere may have been missed. The paper calls for larger prospective studies with age-matched controls.

DOI: 10.1093/jsxmed/qdag258 · Subscription access via the publisher. Approved by IRB H-49807.

Declared interests: The senior author declares consulting relationships with several pharmaceutical and device companies, as published with the article. Dr. Soarawee and the remaining authors declared no competing interests.